TG THERAPEUTICS, INC. Deferred Federal Income Tax Expense (Benefit)
TG THERAPEUTICS, INC. (TGTX) reported Deferred Federal Income Tax Expense (Benefit) of -$335.08 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-27
- TG THERAPEUTICS, INC. deferred federal income tax expense (benefit) for fiscal 2025 was -$335.08M.
- TG THERAPEUTICS, INC. deferred federal income tax expense (benefit) for fiscal 2024 was $0.00.
- TG THERAPEUTICS, INC. deferred federal income tax expense (benefit) for fiscal 2023 was $0.00.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$335.08M 10-K · filed 2026-02-27 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-27 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |